Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
levobupivacaine + tramadol
- Development stage
- Phase 4
- Lead developer
- Endo International
- Modality
- Small Molecules
- Administration
- Caudal, Local Infiltration, Perineural, Epidural, Intrathecal
01
Overview
A combination of levobupivacaine, a local anesthetic agent, and tramadol, a synthetic opioid with local anesthetic properties. This combination is used for local or regional anesthesia and postoperative pain management. The combination provides synergistic analgesic effects, with levobupivacaine blocking sodium channels to prevent nerve impulse propagation while tramadol works through both opioid (weak μ-receptor affinity) and non-opioid mechanisms (inhibition of noradrenaline and serotonin reuptake).
02
Targets
MOR (Mu opioid receptor)NET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on levobupivacaine + tramadol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on levobupivacaine + tramadol.